3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
11
Head and Neck Neoplasms
5
Breast Neoplasms
3
Adenocarcinoma of Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Gliosarcoma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Untreated Childhood Anaplastic Astrocytoma
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Salivary Gland Neoplasms
1
Recurrence
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Lymphoid Interstitial Pneumonia
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Gefitinib
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA